Skip to main content

Table 2 Final estimates of population PK and PD parameters

From: Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study

Parameter Description (units) Estimates from final model Bootstrap results Shrinkage (%)
Estimate % RSEa Median (95% CI)
Fixed effect      
Pharmacokinetic      
  CL/F = θ 1 * (weight/71.65)θ4      
  θ 1 TV of CL/F (L/h) for subject whose weight = 71.65 kg 0.200 2.7 0.1998 (0.1995 – 0.2002)  
  θ 4 Exponent of weight proportional to CL/F 0.845 17.4 0.840 (0.830 – 0.850)  
  V d /F = θ 2 * (weight/71.65)      
  θ 2 TV of V d (L) for subject whose weight = 71.65 kg 8.300 2.7 8.281 (8.267 – 8.295)  
  k f = θ 3 TV of k f (h-1) 0.341 15.1 0.345 (0.341 – 0.348)  
Pharmacodynamic      
  θ 5 TV of EC 50 (μg/mL) 84.9 4.0 85.19 (84.98 – 85.40)  
  θ 6 TV of γ 19.2 22.4 20.70 (20.32 – 21.08)  
BSV (%CV)      
Pharmacokinetic      
  ω 1 2 BSV for CL/F 14.9 21.0 14.4 (14.3 – 14.5) 0.6
  ω 2 2 BSV for V d 9.5 57.8 8.6 (8.4 – 8.8) 40.2
  ω 3 2 BSV for k f 88.0 26.5 73.5 (72.8 – 74.1) 10.5
Pharmacodynamic      
  ω 4 2 BSV for EC 50 21.8 28.4 21.4 (21.2 – 21.5) 8.3
  ω 5 2 BSV for γ 0 (Fixed) NE - -
Residual error (σ2)b      
Proportional error   0.098 6.5 0.0977 (0.0973 – 0.0981) 11.5
  1. % RSE, % relative standard error; CI, confidence interval; CL/F, oral clearance; TV, typical value at population level; V d /F, oral volume of distribution; k f , first-order formation rate constant; EC 50 , HTB concentration at which the probability of IPA is 50%; γ, shape factor; BSV, between-subject variability; % CV, % coefficient of variation; NE, not estimated.
  2. a% RSE is calculated from ω2.
  3. bAdditive residual error was not selected.